Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 259

Posts Tagged ‘cancer’

OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung Cancer

Posted by fidest press agency su giovedì, 27 giugno 2019

OncLive®, the nation’s leading multimedia resource focused on providing oncology professionals with the most current and insightful information they need to provide the best patient care, will host its latest State of the Science Summit™ on Non-Small Cell Lung Cancer (NSCLC) Monday, July 1, from 5-9 p.m. at the Whitley in Atlanta. The summit will be chaired by Suresh S. Ramalingam, MD, FASCO, deputy director, assistant dean for cancer research, director of the lung cancer program and, co-leader of the discovery and developmental therapeutics program at Winship Cancer Institute of Emory University.
This interactive and educational meeting will discuss novel treatments for patients with NSCLC. Expert presenters will delve into informative topics facing lung cancer specialists, oncologists, nurses and other medical professionals, such as screening for NSCLC, stage 1c squamous and nonsquamous NSCLC, EGFR-positive NSCLC, ALK-positive and ROS1 NSCLC, and targetable biomarkers in NSCLC. The presenters will also engage in a peer exchange and address audience questions.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

State of the Science Summit on Non-Small Cell Lung Cancer

Posted by fidest press agency su mercoledì, 12 giugno 2019

OncLive®, the nation’s leading digital resource focused on providing oncology professionals with the most current and insightful information they need to offer the best patient care, will host its latest State of the Science Summit™ on non-small cell lung cancer (NSCLC) on Monday, June 17, from 5 to 9 p.m. at the Boston Marriott Newton in Newton, Massachusetts. The summit will be chaired by Dr. Lecia V. Sequist, Landry Family associate professor of medicine at Harvard Medical School and director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital.
This interactive and educational meeting will discuss novel treatments for patients with NSCLC. Expert presenters will delve into informative topics facing lung cancer specialists, oncologists, nurses and other medical professionals, such as lung cancer screening, radiation oncology, stage 3 NSCLC, stage 4 small-cell lung cancer management, EGFR-positive lung cancer management, ALK-positive lung cancer management and emerging biomarkers in NSCLC. The presenters will also engage in a peer exchange and address audience questions.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Focused on building quality cancer care products

Posted by fidest press agency su lunedì, 3 giugno 2019

Lugano, Switzerland, June 1, 2019 – Helsinn, the Swiss pharmaceutical group focused on building quality cancer care products, in conjunction with the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO), today announces Allison Barz Leahy, MD, University of Pennsylvania, as the recipient of the Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care for 2019.
Conquer Cancer’s Young Investigator Award (YIA) funds physicians who are in the final years of training to aid their transition from a fellowship program to a faculty appointment. The YIA is a one-year $50,000 grant that aims to promote quality research in clinical oncology.The recipient of this endowed YIA, Dr. Allison B. Leahy, received her medical degree from SUNY Upstate College of Medicine. She completed her Pediatric Residency and Pediatric Hematology/Oncology Fellowship at the Children’s Hospital of Philadelphia (CHOP). Dr. Leahy is a recent alumna of the Pediatric Hospital Epidemiology and Outcomes Research Training program managed by the Center for Pediatric Clinical Effectiveness at CHOP and is currently finishing her thesis work for her Master of Science in Clinical Epidemiology from the University of Pennsylvania. Dr. Leahy’s clinical interests include investigating the benefits and barriers of using patient-reported symptom monitoring for children with cancer in an attempt to examine the impact of this type of monitoring on the quality of life, hospitalization rate and illness severity in childhood cancer. Dr. Leahy’s YIA project is entitled Symptom monitoring using patient-reported outcomes in newly diagnosed pediatric cancer patients.Established in 2016, the endowed YIA honors the life of Anna Braglia, the wife of Helsinn Group Founder and Chairman Gabriele Braglia and mother of Helsinn Group Vice Chairman and CEO Riccardo Braglia, who passed away in 2015. Helsinn endowed this award, which is part of Conquer Cancer’s ’s Grants and Award’s Program, to encourage more aspiring physicians to move into all areas of oncology by supporting them as they move from academia into research.Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “Dr. Allison Leahy is an exceptional candidate for this award. Her work on patient-reported outcomes in childhood cancer has the potential to dramatically improve the quality of life for cancer care in children. At Helsinn, we strive to improve the standard of living for individuals with cancer. Dr. Leahy’s work aligns with our goals and visions to put the patient at the heart of the approach cancer care and we are delighted to be able to support her invaluable work. We wish Dr. Leahy the best with her project”
Helsinn is a privately-owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland and the U.S., a representative office in China as well as a product presence in approximately 190 countries globally.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Leading Liver Cancer Scientific Forum

Posted by fidest press agency su mercoledì, 22 maggio 2019

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that the International Liver Cancer Association (ILCA) has accepted Can-Fite’s abstract describing the latest data from the Company’s Phase II Liver Cancer study of Namodenoson for an oral presentation at its annual conference. The oral presentation titled “The Safety and Efficacy of Namodenoson in the Second Line Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients with Underlying Child-Pugh B (CPB) Liver Cirrhosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled” will be delivered on September 22, 2019 during the Novel Targets and Prognostic Markers Session from 11:00 am to 12:30 pm. The ILCA’s 13th Annual Conference will take place from September 20 to 22, 2019 in Chicago, Illinois.The ILCA is the only international organization devoted exclusively to liver cancer research for experts from all related disciplines. Its mission is to lead a global community of physicians, scientists and allied professionals through education and research with the goal to better prevent and treat liver cancer.“This is a very prestigious conference that brings together the leading thought leaders, researchers, and physicians in the treatment of liver cancer. Governing members of the ILCA thoroughly research each abstract submission and select those that are most relevant to the advancement of treating liver cancer. We are pleased that the selection committee sees the potential of Namodenoson as a treatment for advanced liver cancer patients with severe liver dysfunction. Based on both safety and efficacy in this Phase II study, Can-Fite is preparing a Phase III trial,” stated Can-Fite CEO Pnina Fishman.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

20th Annual International Lung Cancer Congress

Posted by fidest press agency su mercoledì, 8 maggio 2019

Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education, will host the 20th Annual International Lung Cancer Congress® from July 25 to 27 at the Huntington Regency Huntington Beach in California. The program will be chaired by Dr. David R. Gandara, professor of medicine in the division of hematology/oncology at the University of California (UC) at Davis School of Medicine and the director of the thoracic oncology program and senior adviser to the director at UC Davis Comprehensive Cancer Center, and Dr. Roy S. Herbst, Ensign professor of medicine (medical oncology), professor of pharmacology, chief of medical oncology and associate director for translational research at Yale Cancer Center, Yale School of Medicine.
The 20th Annual International Lung Cancer Congress® is a three-day program for surgical, medical and radiation oncologists interested in the treatment of patients with lung cancer. During this meeting, leading international and national experts will provide perspectives on how to incorporate the latest data on targeted agents, immunotherapy, surgery and radiation oncology in the clinic through a series of cutting-edge lectures, panel discussions, multidisciplinary tumor boards and interactive Q&A sessions. Attendees who participate will have the opportunity to engage with faculty as they share their perspectives and personal experiences on the clinical challenges and ongoing controversies in lung cancer management.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Precision Medicine for Pediatric Cancer

Posted by fidest press agency su martedì, 19 marzo 2019

Research performed over the last several decades has led to an increased understanding of the genetics of cancer. The clinical application of this knowledge for pediatric cancer has lagged behind studies performed for adults. In a perspectives article published in the prestigious journal Science, Dr. Jaclyn Biegel, from Children’s Hospital Los Angeles, and Dr. Alejandro Sweet-Cordero, of the University of California, San Francisco, survey the landscape of this young field and present opportunities for using genomic information to advance a new era of care for children with cancer.Cancer arises from genetic changes, including DNA mutations, that are either present at birth, or are acquired over time. Many adult cancers are initiated by mutations acquired through exposure to substances like smoking and radiation or simply from aging. The tumors may contain hundreds of sequence alterations, and identifying which changes drive the growth of the tumors and impact treatment response can be challenging. In contrast, pediatric malignancies often develop from a very small number of mutations, only some of which overlap with the types of mutations seen in adult cancers. Furthermore, an estimated 20% of pediatric cancers arise in children who have a genetic predisposition to malignancy. For this reason, the clinical genetic assays developed to inform prognosis and treatment decisions for adult cancers have not been as useful in pediatrics.
OncoKids® was one of the first next-generation sequencing panels to detect DNA and RNA changes that characterize pediatric cancers. The panel was developed at Children’s Hospital Los Angeles under the guidance of author Jaclyn Biegel, PhD, FACMG, Director of CHLA’s Center for Personalized Medicine. The OncoKids® panel provides a molecular diagnosis, informs prognosis, and highlights novel therapeutic targets across the broad spectrum of cancers in children, including leukemias, brain tumors and other solid tumors.
Although tremendous progress has been made in pediatric cancer care, treatment resistant disease and relapse continue to negatively impact patient outcomes. Genetic profiling of pediatric cancers is typically done at the time of diagnosis or at the time of relapse to help determine treatment planning. According to Dr. Biegel, future studies that may be performed over the course of treatment and at remission have the potential to provide critical information about the mechanisms of tumor progression, treatment resistance and metastasis.Tremendous opportunity exists for changing outcomes in children with cancer by using an integrated approach to evaluating children and their families that includes genomic medicine as a central component in their care.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

36th annual Miami Breast Cancer Conference

Posted by fidest press agency su sabato, 2 febbraio 2019

Physicians’ Education Resource® (PER®), a leading resource for continuing medical education (CME), announces Dr. Gregory Stock and Stephanie Seban as the keynote speakers for the 36th annual Miami Breast Cancer Conference®. This year’s keynote presentations will take place at the Fontainebleau in Miami Beach, Florida.
For 36 years, the Miami Breast Cancer Conference® has brought together surgical, medical and radiation oncologists, as well as geneticists, pathologists, radiologists and supportive-care specialists, to foster awareness of state-of-the-art treatments for all stages and subtypes of breast cancer, provide expert perspectives on areas of clinical uncertainty or controversy, and encourage attendees to engage in cross-team cooperation in their clinics. The four-day interactive conference will explore all aspects of treatment and management of breast cancer, including screening, molecular and genetic testing, detection, primary treatments and patient-support strategies. The conference will also feature a special patient communication workshop, specialized programming on issues related to young women with breast cancer and a discussion about physician burnout.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

CURE® to Host First-Ever Patient-Focused Session at the 36th Annual Miami Breast Cancer Conference

Posted by fidest press agency su giovedì, 24 gennaio 2019

CURE Media Group, which reaches over 1 million patients, survivors and caregivers across an industry-leading multichannel platform devoted solely to cancer updates, research and education, will host a patient-track meeting on Saturday, March 9, at the Fontainebleau Miami Beach in Florida during the Physicians’ Education Resource® Miami Breast Cancer Conference®.“We are excited to host a patient-focused track for the first time at this year’s Miami Breast Cancer Conference®,” said Michael J. Hennessy Jr., president of MJH Associates Inc., parent company of CURE® magazine. “This track gives patients the opportunity to network and educate themselves on important topics surrounding treatment, BRCA and clinical trials.”
The keynote speaker for the meeting will be Patrick Borgen, M.D., chair of the department of surgery at Maimonides Medical Center in Brooklyn, New York. The meeting will take place from 7:30 a.m. to 5:00 p.m. Following an optional yoga session, attendees will be provided with breakfast and lunch between the many sessions and expert panels directed toward patients with breast cancer. Topics will include managing side effects of treatment, survivorship care planning, genetic counseling and psychosocial, behavioral and communication issues in breast cancer care.CURE®’s full-day, patient-focused event is hosted in tandem with the Miami Breast Cancer Conference®. For 36 years, the Miami Breast Cancer Conference® has brought together surgical, medical and radiation oncologists, as well as geneticists, pathologists, radiologists and supportive-care specialists, to foster attendees’ awareness of state-of-the-art treatments for all stages and subtypes of breast cancer.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

FotoFinder Systems: Artificial Intelligence Revolutionizes Skin Cancer Detection

Posted by fidest press agency su venerdì, 11 gennaio 2019

“Artificial Intelligence” (AI) is currently on everyone’s lips. Experts say companies need to focus on three aspects of AI to play a leading role in the topic: latest programming insights, importance of data and AI integration into existing workflows. FotoFinder Systems already combines these key aspects today. As a pioneer, the high-tech company is a leader in integrating AI into technology for skin cancer diagnostics. With the new expert software Moleanalyzer pro, dermatologists are able to assess moles with AI. Validation results confirm an extremely high accuracy. Moleanalyzer pro offers physicians the possibility to confirm their diagnosis with various evaluation techniques. For the first time, it is possible to combine specialist expertise with AI and additionally to receive a second opinion – per mouse click – from renowned international skin cancer experts.Moleanalyzer pro works with deep learning: The human ability to learn from examples and experiences was transferred to the computer. For this purpose the “Convolutional Neural Network” (CNN) was trained with the currently largest data collection of dermoscopic images including corresponding diagnosis. Due to many years of valuable cooperation with physicians worldwide, the continuous “feeding” of the algorithm succeeds. With growing experience and its own autonomous rules, it is able to distinguish between benign and malignant lesions. The result is a score that supports the risk assessment of both melanocytic and non-melanocytic skin lesions. Shortly, this AI Score will be available for doctors also on mobile devices.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Colorectal Cancer Screening Programs

Posted by fidest press agency su venerdì, 12 ottobre 2018

Clinical Genomics, the manufacturer of the InSure ONE fecal immunochemical test (FIT), is pleased to discuss the new American Cancer Society (ACS) Colorectal Cancer Screening Guidelines with Family Medicine Physicians. In the new guidelines published in May 2018, ACS now recommends that starting at age 45 years, adults with an average risk of colorectal cancer undergo regular screening with either a high-sensitivity stool-based test or a structural (visual) examination, depending on patient preference and test availability. Six testing options are recommended, including FIT annually and colonoscopy every 10 years. According to the ACS, the reason for lowering the age range was based on the marked increase in colorectal cancer amongst younger adults. The ACS reported a 51% increase among those individuals under the age of 55 between 1994 and 2014.InSure ONE, a convenient at-home collection FIT, intended to detect blood in stool, is easy to use, and may improve compliance for screening programs. Unlike other FITs, InSure ONE simply requires a sample of water from the toilet bowl following a single bowel movement. Sample collection is completed in minutes using a long-handled brush and does not require the user to collect, handle, or smear fecal matter.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

US Thyroid Cancer Market and Competitive Landscape 2014-2018 & Forecast to 2023

Posted by fidest press agency su venerdì, 12 ottobre 2018

US Thyroid Cancer Market and Competitive Landscape – 2018 provides comprehensive insights into Thyroid Cancer pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares. This study accurately estimates and forecast Thyroid Cancer market size and drug sales. This research also provides insights into Thyroid Cancer epidemiology and late stage pipeline. The research is classified into following sections – Thyroid Cancer overview with definitions, symptoms, etiology, diagnosis, treatment options; Thyroid Cancer pipeline insights covering late stage clinical trials pipeline; Thyroid Cancer prevalence trends by countries; Thyroid Cancer market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Various studies associate socioeconomic disadvantage and higher rates of cancer

Posted by fidest press agency su sabato, 16 giugno 2018

People with a more disadvantaged socioeconomic position in society are more likely to develop different types of cancer, according to the compilation of studies carried out by LIFEPATH, a project funded by the European Commission with the aim of investigating the biological pathways underlying social differences in healthy ageing.The purpose of this analysis is to summarise investigations on social-to-biological processes occurring over the life course with an emphasis on processes involved in social inequalities in cancer. LIFEPATH uses a multidisciplinary approach integrating information on the socioeconomic position, environmental exposures and risk factors with biological measurements. The latest findings illustrate the potential impact of the socioeconomic position upon many pathological processes, including cancer. The analysis carried out by LIFEPATH shows that inflammatory and immune system dysregulations and biological ageing are more commonly found in disadvantaged social backgrounds. Both are closely related to cancer. Despite this, social inequalities remain neglected as a public health imperative, not clearly identified as a risk factor in public policies as tobacco and sedentary lifestyle are. Overweight and obesity have been shown to have a social pattern from early childhood. In a large study carried out by Dr Cathal McCrory, from The Irish Longitudinal Study on Ageing (TILDA), it was observed that parent and child body mass index (BMI) is linked to low socio-economic position from age three and remains so across the early childhood years. Thanks for the researches made by Dr Maria Kyrgiou (Imperial College of London) and summarized by IARC (Lauby-Secretan, International Agency for Research on Cancer), there is evidence thathigher BMI may produce a dysregulation in the cellular and molecular mediators of immunity and inflammation, both related to cancer. Another set of important social-to-biological mechanisms involving the immune system may be set up in childhood. A study by V. Garès and colleagues showed that children from more disadvantaged social backgrounds are more likely to be infected by a ubiquitous herpes virus called Epstein Barr virus (EBV). EBV is involved in certain types of cancers (including nasopharyngeal carcinoma, Burkitt lymphoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disorder). “The main interest of this finding is that early acquisition of pathogens affects the maturation of the immune system and in turn affects its function either positively or negatively”, says Paolo Vineis, Professor at the Imperial College of London and leader of the LIFEPATH project.Among adults, a large multi-cohort study which investigated the relationship between socioeconomic adversity, risk factors and mortality, showed that social inequalities are associated with a 2.1-year reduction in life expectancy between ages 40 and 85 years. This was the strongest association with life expectancy, just after smoking (4,8 years), diabetes (3,9 years) and physical inactivity (2,4 years). Another analysis focused more specifically on how the educational attainment of individuals is related to an epigenetic mechanism, DNA methylation, used to represent overall biological ageing. Carried out by Giovanni Fiorito (Italian Institute for Genomic Medicine) it suggests that individuals with a lower level of education experience a higher rate of biological ageing than those with a high education level. The analyses controlled for a number of behavioural factors, but nevertheless accelerated ageing among the more socially disadvantaged remained present. Socioeconomic adversity may be associated with accelerated epigenetic ageing, implicating biomolecular mechanisms that link social circumstances to age-related diseases and longevity.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Dendreon Publishes New Data in Clinical Cancer Research

Posted by fidest press agency su martedì, 5 giugno 2018

Dendreon Pharmaceuticals LLC, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, today announced publication of new data in Clinical Cancer Research, a journal of the American Association for Cancer Research, showing that treatment with PROVENGE® (sipuleucel-T) generates killer T cells that target prostatic acid phosphatase (PAP), a protein expressed on the majority of prostate cancer cells. The results of this analysis provide further evidence around the relationship between killer T cell activity and overall survival in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC).“This research suggests the role of sipuleucel-T in the generation of killer T cells following treatment,” said Charles G. Drake, M.D., Ph.D., director of genitourinary oncology at Columbia University Medical Center and senior author. “Importantly, these data suggest how the mechanism of action of sipuleucel-T may, in part, translate into survival benefit for patients.”To quantify potential cytotoxic T lymphocyte (CTL) activity, cell-surface CD107a expression on PAP-specific CD8+ T cells was measured in samples from a subset of patients enrolled in Dendreon’s STAMP clinical trial (study ID: P11-3) before and after sipuleucel-T treatment. It was observed that T cells were able to recognize and target PAP only after sipuleucel-T treatment, with responses observed at 6 weeks and sustained out to 26 weeks post-treatment. Importantly, the magnitude of the CTL activity at week 26 correlated with increased overall survival, indicating that PROVENGE evokes a memory T cell response that may play a role in the survival benefit of PROVENGE.“While the IMPACT trial established the survival benefit of sipuleucel-T, the mechanism of action of treatment has not been fully appreciated,” said Bruce A. Brown, M.D., senior vice president, medical, at Dendreon. “This research provides more information about how sipuleucel-T works and – for the first time – correlates the magnitude of killer T cell activity with overall survival.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

“New Drugs on the Horizon”

Posted by fidest press agency su sabato, 7 aprile 2018

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that it has been selected for one invited lecture and three poster presentations at the Annual Meeting of the American Association for Cancer Research (AACR), being held from April 14 through April 18 in Chicago, Illinois.A presentation describing the discovery of BT1718 will be given by Bicycle’s Chief Scientific Officer Nicholas Keen, Ph.D. in the New Drugs on the Horizon Session. BT1718 is a Bicycle Toxin Conjugate offering a completely new approach to the treatment of cancer, and it is currently being evaluated in a Phase I/IIa study sponsored by Cancer Research UK, the world’s leading charity dedicated to cancer research.“We are honoured to have been selected to describe the discovery of BT1718 in the New Drugs on the Horizon session and look forward to sharing our preclinical data as well as providing a clinical update,” said Dr. Keen. “BT1718 represents a new and highly differentiated approach to the treatment of cancer and is being developed through a unique collaborative partnership with Cancer Research UK, which provides important access to world-class operational infrastructure and strong drug development expertise.”In the three poster presentations, Bicycle will present new data on its rapidly expanding preclinical pipeline, including two posters on the development of BT5528, a Bicycle Toxin Conjugate targeting EphA2, which is a tumour antigen highly expressed in difficult to treat cancers associated with poor prognosis. The company will also present new data describing the discovery and chemical optimisation of the first fully synthetic CD137 agonist, representing a new class of multimeric Bicycle T-cell modulators.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

MUSC Health and Alliance Oncology Expand Cancer Care in Beaufort, S.C.

Posted by fidest press agency su mercoledì, 7 febbraio 2018

san frnciscoSan Francisco. Alliance Oncology and the Medical University of South Carolina Health System (MUSC Health) announced today that they will partner with Beaufort Memorial Hospital to relocate and expand the hospital’s radiation oncology center to its main campus in late 2018. This project represents Alliance Oncology’s vision to be a driver in transforming healthcare by partnering with leading providers to expand regional services to communities – thus giving patients and their providers improved access, convenience and services closer to home. “In partnership with MUSC Health and Beaufort Memorial Hospital we are excited to add this location benefitting the local Beaufort community, and to augment academic cancer care services in the region,” said Greg Spurlock, President of Alliance Oncology. “As one of the nation’s leading providers of cancer care, this center will join Alliance affiliated locations across the country in providing high-quality, patient-centered services in partnership with premier cancer care providers and caregivers.” At the new Beaufort Memorial Keyserling Cancer Center, an MUSC clinical advisory committee will collaborate closely with local oncology experts and a dedicated clinical liaison will be onsite in the radiation oncology center. This expands upon the collaboration that was formed in 2016 when Beaufort Memorial Keyserling Cancer Center began enrolling qualifying cancer patients in clinical trials through an affiliation with the National Cancer Institute-designated Hollings Cancer Center at MUSC. “Given the needs of our patients throughout the state, it is imperative that we find innovative affiliations such as this one to ensure we are reaching all of those who need the expertise of our teams,” said Patrick J. Cawley, M.D., CEO, MUSC Health and Vice President for Health Affairs at Medical University of South Carolina. “We are excited and pleased to work with our colleagues at Alliance Oncology and Beaufort Memorial to bring the expertise of the Hollings Cancer Center even closer to those who need us.” “Beaufort Memorial Hospital has been providing outstanding cancer care to the community for more than a decade,” says Russell Baxley, MHA, President and CEO of Beaufort Memorial Hospital. “Our new and expanded partnership with MUSC and Alliance Oncology allows us to offer cutting-edge technology and resources locally, providing the latest in cancer care to our patients.”Alliance Oncology partners directly with hospitals and physicians to develop fully integrated oncology programs. Providing a full range of inpatient and outpatient service line capabilities, Alliance Oncology’s comprehensive approach to cancer care affords its partners the speed-to-market, quality clinical outcomes, patient satisfaction and operational expertise that sets them apart from the competition. (foto: san francisco)

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer

Posted by fidest press agency su mercoledì, 3 gennaio 2018

cancerAgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced a newly-published peer-reviewed study that reveals genes implicated in tissue regeneration, cancer, and aging. The study, by scientists at AgeX and BioTime, in collaboration with Insilico Medicine, utilized artificial intelligence (AI) technology to parse millions of gene expression data points to decipher the complex mechanisms controlling natural tissue regeneration. The results, published in the peer-reviewed scientific journal Oncotarget, showed that the candidate genes are expressed differently in tissues early in development when they are capable of regeneration compared to later in life when regeneration can no longer take place. Surprisingly, some of the genes, including one highlighted in the study, COX7A1, displayed a rare profile of being nearly universally dysregulated in diverse types of cancer. The discoveries may lead to novel strategies to induce Tissue Regeneration (iTRTM) in the context of trauma or age-related degenerative disease, as well as treat and diagnose cancer.“It is rare to find genes implicated in tissue regeneration, let alone with abnormal expression in so many diverse cancer types such as those of the breast, lung, kidney, bone, and muscle,” said Michael D. West, PhD, CEO of AgeX and co-CEO of BioTime. “AgeX has certain rights to use the associated patent applications and to commercialize related therapeutic and diagnostic applications. Since we believe unlocking the natural ability of the human body to regenerate tissues afflicted with degenerative disease is a very large market opportunity, we are aggressively developing products using the technology.”A short video is available online describing the discovery and its implication for product development at AgeX. Included in the video is a discussion of an iTR product designated RenelonTM, which, in its first generation form, utilizes a repurposed drug and may therefore have a relatively short development timeline.“The embryonic-to-fetal transition (EFT) deciphered in this study is emerging as a wonderful new arena in which to explore the enhancement of regenerative capacity in old age, which is the core of AgeX’s mission,” said Aubrey de Grey, PhD, VP of New Technology Discovery at AgeX. “The discovery of a subunit of the respiratory chain as a key EFT marker dovetails this research fascinatingly with age-related changes in mitochondrial function, which have long been a priority in the anti-aging field and in my own work.”“BioTime and AgeX Therapeutics are at the forefront of regenerative medicine,” commented Alex Zhavoronkov, PhD, CEO of Insilico Medicine. “By utilizing their heavy investment in large-scale, highly-controlled experiments and their unique expertise in regenerative medicine we managed to develop the AI-powered system for cell and tissue sample profiling. We utilized this system to identify the important genes implicated in the EFT, and possibly in aging. This collaboration started in 2015 when deep leaning methods were in their infancy and required two years to diligently validate the outcomes. We learned that domain expertise is just as important as expertise in AI.”

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Juno Therapeutics to Present at November 2017 Investor Conferences

Posted by fidest press agency su mercoledì, 8 novembre 2017

cancerJuno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in November. The presentations will feature a business overview and update by Steve Harr, Juno’s Chief Financial Officer and Head of Corporate Development.
Juno will present at the 26th Annual Credit Suisse Healthcare Conference at 9:15 a.m. Mountain Time (MT) on Wednesday, November 8, 2017.
Juno will present at the Evercore ISI Biopharma Catalyst / Deep Dive Conference at 8:45 a.m. Eastern Time (ET) on Wednesday, November 29, 2017.
The webcasts will be accessible on the Investor Relations page of Juno’s website at http://www.JunoTherapeutics.com. A replay of each presentation will be available at the same location for 30 days following the corresponding conference.
Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Vedanta Biosciences to Advance Cancer Immunotherapy Candidates

Posted by fidest press agency su giovedì, 2 novembre 2017

tumore metastatico1Vedanta Biosciences, an affiliate of PureTech Health (LSE: PRTC) developing a new category of therapies for immune and infectious diseases based on rationally designed consortia of human microbiome-derived bacteria, today announced that it has exclusively sub-licensed key intellectual property from JSR Corporation to develop and commercialize microbiome-derived cancer immunotherapies based on live biotherapeutics. These live biotherapeutics have been shown to activate CD8+ T cells, a type of white blood cell that is the predominant effector in cancer immunotherapy. The sub-licensed intellectual property is based on the pioneering research of Dr. Kenya Honda, Professor, of Keio University School of Medicine and his collaborators in the University of Tokyo in Japan. An IND filing for the lead product candidate is planned in 2018.“Dr. Honda’s research suggests an entirely new approach to cancer immunotherapy harnessing the human microbiome, which has the potential to significantly enhance the effectiveness of cancer therapies,” said Bernat Olle, PhD, Chief Executive Officer of Vedanta Biosciences. “We are actively developing product candidates containing defined bacterial consortia that activate CD8+ T cells and stimulate the immune system to fight cancer alone and in combination with checkpoint inhibitors. This license to additional intellectual property from Dr. Honda’s institution further strengthens Vedanta’s leading IP position in the microbiome field.” In validated pre-clinical models of cancer, Vedanta’s orally administered product candidates containing defined bacterial consortia induced CD8+ T cells, potentiating the immune system’s attack of tumor cells. The tumor fighting effects of a variety of checkpoint inhibitors were significantly amplified when combined with the bacterial consortia, suggesting a potentially novel approach for combination cancer immunotherapy.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Immune-stimulatory Activity with RGX-104 in Advanced Cancer Patients

Posted by fidest press agency su lunedì, 30 ottobre 2017

PhiladelphiaPhiladelphia. Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today preliminary data from an ongoing Phase 1a/b clinical trial with its lead oral investigational agent, RGX-104. These data demonstrate immune-stimulatory activity in solid tumor patients with highly-refractory malignancies, including patients who have failed prior checkpoint inhibitors. Also presented were pre-clinical data establishing the immune-modulatory and anti-tumor effects of RGX-104. The company presented the data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia. RGX-104 is a liver X receptor (LXR) agonist that upregulates the expression of the target gene, Apolipoprotein E (ApoE), triggering several downstream effects via ApoE receptors. In pre-clinical data presented today, treatment with RGX-104 in mouse models resulted in dual effects on myeloid-derived suppressor cells (MDSCs) and dendritic cells (DCs), both innate immune cells that play a central role in regulating anti-tumor immunity and response to checkpoint inhibitors. Innate immune activation with RGX-104, coupled with a reduction in tumor blood vessels, resulted in anti-tumor activity as a monotherapy as well as synergy with checkpoint inhibitors (CPI) in several drug-resistant mouse models. These data provide rationale for Rgenix’s ongoing Phase 1a/b trial of RGX-104 in advanced cancer patients and support evaluation of RGX-104 as both a monotherapy as well as in combination with CPIs.
As part of the ongoing Phase 1a/b clinical trial, 15 patients with a variety of solid tumors have been treated with escalating doses of RGX-104 monotherapy. Patients treated with RGX-104 had a median of six prior therapies with a range of 1-12, highlighting a population of patients with profoundly resistant disease.Activation of the LXR-ApoE pathway with oral administration of RGX-104 was associated with immune-stimulatory activity in 9 of 10 evaluable patients. This was demonstrated by an increase (up to 11-fold) in activated circulating PD-1+CD8+ T cells during treatment. T cell activation was observed in patients who experienced modulation of the innate immune system during treatment. The effect of RGX-104 on the innate immune system consisted of both MDSC depletion (up to 95% decrease) as well as DC activation as indicated by induction of PD-L1 expression (up to 100% increase). In most cases these effects were observed within two weeks of treatment initiation and generally preceded the onset of T cell activation.
Safety data demonstrate good tolerability with on-target safety findings in the first three dosing cohorts. One patient experienced a DLT of grade 4 reversible neutropenia – a known potential effect of LXR agonism – that reversed within one week, allowing the patient to subsequently tolerate a 50% dose reduction. No MTD has been reached to date. Stable disease has been observed in 4 of 12 evaluable patients, including three who have failed prior checkpoint inhibitor therapy, for periods of at least 8 weeks.Rgenix plans to enroll subsequent dose-escalation cohorts of the RGX-104 monotherapy trial in Q4 2017. Additionally, Rgenix is planning to initiate the Phase 1b expansion component of the study, comprised of disease directed cohorts receiving RGX-104 monotherapy as well as cohorts receiving RGX-104 combined with a CPI, projected to begin in 1H 2018.The LXR-ApoE pathway was discovered as a cancer target using a microRNA (miRNA) based target discovery approach originally developed at The Rockefeller University and now exclusively licensed to Rgenix.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Augmenix Announces Positive Clinical Trial Results Demonstrating Efficacy of SpaceOAR

Posted by fidest press agency su venerdì, 29 settembre 2017

prostateResearchers have long known that higher radiation doses (dose escalation) are more effective at killing tumors. However, the amount of radiation safely delivered to the prostate is limited by the rectum proximity, and concerns of creating long-term rectal injury and associated side effects. Physicians at the University of Texas Southwestern Medical Center and Memorial Sloan Kettering Cancer Center recently evaluated 44 men receiving SpaceOAR Hydrogel followed by dose-escalated (45 Gray) SBRT. The data show that SpaceOAR Hydrogel significantly reduces rectal injury in men undergoing high-dose SBRT for prostate cancer. Specifically, 13.6 percent of treated men had rectal mucosal injury in the study, all of which were mildly symptomatic and completely healed within six months following treatment. These findings are significant, as prior clinical research found that 90 percent of non-SpaceOAR Hydrogel patients treated with the same SBRT regimen experienced similar radiation-induced mucosal injury due to higher rectal wall radiation doses. None of the patients exhibited signs of biochemical cancer recurrence in the 12-month follow up period.“Hypofractionated approaches are gaining momentum in the treatment of prostate cancer, and in our experience, high-dose regimens have provided exceptionally high rates of biochemical control, but at the cost of an increased risk of rectal complications associated with the rectal wall dose,” said Michael Folkert, MD, radiation oncologist and brachytherapy specialist at University of Texas Southwestern Medical Center in Dallas. “Our new study demonstrates that use of the perirectal hydrogel spacer gets us the ‘room’ we need to safely deliver the most potent therapeutic doses to patients, which may ultimately lead to the optimal cancer control while significantly reducing the risk of treatment related complications.” As the first and only prostate cancer spacing device to receive Food and Drug Administration (FDA) clearance, SpaceOAR Hydrogel is placed between the prostate and rectum, protecting the rectum and surrounding tissue from high-dose radiation exposure. Long-term clinical data has shown that at both three and five years post-radiation therapy (using Intensity Modulated Radiation Therapy), patients treated with SpaceOAR Hydrogel demonstrated significant bowel, urinary and sexual function benefits.1-3
“We are excited by the successful results from this study, as it is the first time we’ve evaluated SpaceOAR Hydrogel in prostate cancer patients treated with high-dose SBRT, and the findings confirm a significant clinical benefit,” said John Pedersen, CEO, Augmenix. “As this robust data indicates – along with the other positive data on our hydrogel spacing technology presented this week at ASTRO – we remain steadfast in our vision to develop disruptive medical technology that improves the lives of patients receiving radiation therapy.”Prior SpaceOAR Hydrogel clinical studies have demonstrated significant reductions in long-term radiation side effects, and improvements in patient quality of life following the delivery of standard prostate radiation doses. This recent study was designed to see if SpaceOAR Hydrogel allows for safe prostate dose escalation, which if proven safe in other studies, has the potential to reduce cancer recurrence rates following prostate radiotherapy.For more information on SpaceOAR Hydrogel, visit http://www.SpaceOAR.com. (photo: prostate)

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »